



UPPSALA  
UNIVERSITET

# Implementing Optimal Designs for Dose-Response Studies through Adaptive Randomization for a Small Population Group

Yevgen Ryznik<sup>1,2</sup>, Oleksandr Sverdlov<sup>3</sup>, Andrew C. Hooker<sup>2</sup>

<sup>1</sup>Department of Mathematics, Uppsala University

<sup>2</sup>Department of Pharmaceutical Biosciences, Uppsala University

<sup>3</sup>Novartis Institutes for BioMedical Research

PODE 2017

- 1 Motivation
- 2 Randomization targeting (un)equal allocation
- 3 Simulation study
- 4 Summary



UPPSALA  
UNIVERSITET

# Outline

- 1 Motivation
- 2 Randomization targeting (un)equal allocation
- 3 Simulation study
- 4 Summary

# Accelerated Failure Time (AFT) Model

Let  $T > 0$  be a time-to-event variable:

$$T \sim Weibull(\lambda, p).$$

We consider the following AFT model with a single covariate  $x$ :


$$\log T = \beta_0 + \beta_1 x + \beta_2 x^2 + b\varepsilon,$$

where

- $x$  corresponds to a dose (treatment arm),
- scale parameter:  $\lambda = \exp(\beta_0 + \beta_1 x + \beta_2 x^2)$ ,
- shape parameter:  $p = b^{-1}$ ,
- and  $\varepsilon \sim f_\varepsilon(v) = \exp(v - \exp(v))$  – *extreme value distribution*.


# Accelerated Failure Time (AFT) Model

Dose-response relationship:  $Median(T|x) = \exp(\beta_0 + \beta_1 x + \beta_2 x^2) \{\log(2)\}^b$





# Censoring



# Likelihood and Fisher Information

- For a sample of  $n$  patients and a vector of parameters  $\boldsymbol{\theta} = (\boldsymbol{\beta}^T, b)^T$  one can calculate *log-likelihood function*  $\log \mathcal{L}(\boldsymbol{\theta})$ .
- Then, *MLEs* of unknown model parameters ( $\hat{\boldsymbol{\theta}}_{MLE}$ ) are the solutions of score equations

$$\frac{\partial \log \mathcal{L}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta}} = \begin{pmatrix} \frac{\partial \log \mathcal{L}(\boldsymbol{\theta})}{\partial \boldsymbol{\beta}} \\ \frac{\partial \log \mathcal{L}(\boldsymbol{\theta})}{\partial b} \end{pmatrix} = \mathbf{0}$$

- The corresponding *Fisher Information Matrix* is

$$I(\boldsymbol{\theta}) = -\mathbf{E} \left( \frac{\partial^2 \log \mathcal{L}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta} \partial \boldsymbol{\theta}^T} \right)$$

## Experimental Design

A  $K$ -points design is determined by a discrete probability measure

$$\xi = \begin{pmatrix} x_1 & x_2 & \dots & x_K \\ \rho_1 & \rho_2 & \dots & \rho_K \end{pmatrix},$$

where

- $K$  is a number of doses (treatment arms).
- $x_1, x_2, \dots, x_K$  are selected doses.
- $\rho_1, \rho_2, \dots, \rho_K$  are proportions of subjects assigned to corresponding doses.

$$x_k \in \mathcal{X} = [0; 1], \quad \sum_{k=1}^K \rho_k = 1.$$



## Experimental Design

A  $K$ -points design is determined by a discrete probability measure

$$\xi = \begin{pmatrix} x_1 & x_2 & \dots & x_K \\ \rho_1 & \rho_2 & \dots & \rho_K \end{pmatrix},$$

where

- $K$  is a number of doses (treatment arms) –  **$K$  is to be determined.**
- $x_1, x_2, \dots, x_K$  are selected doses – **doses are to be determined.**
- $\rho_1, \rho_2, \dots, \rho_K$  are proportions of subjects assigned to corresponding doses – **proportions are to be determined.**

$$x_k \in \mathcal{X} = [0; 1], \quad \sum_{k=1}^K \rho_k = 1.$$

## D-optimal Design

- For a given design  $\xi$  the full *Fisher Information Matrix* is

$$FIM(\xi, \boldsymbol{\theta}) = n \sum_{k=1}^K \rho_k I(\boldsymbol{\theta} | x_k).$$

- Then, a *D-optimal design* is determined as a solution of the following optimization problem

$$\xi_D^* = \arg \max_{\xi} |FIM(\xi, \boldsymbol{\theta})|.$$



## D-optimal Design

Without censoring, *D-optimal design* is a *3-points balanced (uniform) design*


$$\begin{pmatrix} 0 & 0.5 & 1 \\ 1/3 & 1/3 & 1/3 \end{pmatrix},$$

where  $\begin{bmatrix} 0 \\ 0.5 \\ 1 \end{bmatrix}$  – minimum dose  
                  – average dose  
                  – maximum dose



# D-optimal Design

In the presence of censoring *D-optimal design* still has 3 points but *it is shifted from the uniform design*.





**Q:** Given (D-)optimal design  $\xi^*$  and sample size  $n$ , how to implement it in practice, i.e. *how to target optimal proportions*  $\rho_k^*, k = 1, 2, \dots, K$  ?



**Q:** Given (D-)optimal design  $\xi^*$  and sample size  $n$ , how to implement it in practice, i.e. *how to target optimal proportions*  $\rho_k^*, k = 1, 2, \dots, K$  ?

**A:** To choose a proper *randomization procedure!*

- 1 Motivation
- 2 Randomization targeting (un)equal allocation**
- 3 Simulation study
- 4 Summary

## Requirements for a “Good” Randomization Procedure

- **Balance**

- Treatment group sizes should be very close to the desired target allocation ratio, *throughout the course of the trial*

- **Randomness**

- The procedure should have low proportion of deterministic assignments to minimize chance of selection bias

- **Known statistical properties**

- The procedure should have *established statistical properties* and should lead to *valid statistical inference* at the end of the trial

- **Ease of implementation**





# Notations used

 $K$ Number of treatment arms ( $K \geq 2$ ) $w_1 : w_2 : \dots : w_K$ Target allocation ratio (integers with  $GCD = 1$ )

$$\rho_k = \frac{w_k}{\sum_{k=1}^K w_k}$$

Target allocation proportions

$$(0 < \rho_k < 1, \sum_{k=1}^K \rho_k = 1)$$

 $n$ 

Total sample size for the trial

 $N_1(j), N_2(j), \dots, N_K(j)$ Treatment group sizes after  $j$  subjects have been randomized ( $N_1(j) + N_2(j) + \dots + N_K(j) = j$ ) $P_1(j), P_2(j), \dots, P_K(j)$ Randomization probabilities to treatments 1, 2,  $\dots$ ,  $K$  for the  $j$ -th subject ( $0 \leq P_k(j) \leq 1$  and  $P_1(j) + P_2(j) + \dots + P_K(j) = 1$ )



## Example

- Design

$$\xi = \begin{pmatrix} 0 & 0.25 & 0.59 \\ 0.39 & 0.35 & 0.26 \end{pmatrix}$$

- $K = 3$  (a three-arm trial)
- $\rho_1 = 0.39$ ,  $\rho_2 = 0.35$ ,  $\rho_3 = 0.26$  – target allocation proportions for treatments 1, 2, 3
- $n = 100$  – total sample size
- It is desirable to achieve final sample sizes as follows:

$$N_1 = 39, N_2 = 35, N_3 = 26,$$

i.e. target allocation ratio is

$$w_1 : w_2 : w_3 = 39 : 35 : 26$$

- It is also desirable to have  $j^{-1}N_k(j) \approx \rho_k$ ;  $k = 1, 2, 3$  throughout the trial, while maintaining the randomized nature of the experiment

# Randomization Procedures for Unequal Allocations

- 1 Completely Randomized Design – CRD
- 2 Permuted Block Design – PBD( $b$ )
- 3 Block Urn Design – BUD( $\lambda$ )
- 4 Mass Weighted Urn Design – MWUD( $\alpha$ )
- 5 Drop-the-Loser Rule – DL( $\alpha$ )
- 6 Doubly Adaptive Biased Coin Design – DBCD( $\gamma$ )
- 7 Constraint Balance Randomization – MaxEnt( $\eta$ ) and MinQD( $\eta$ )

# Randomization Procedures for Unequal Allocations

- 1 Completely Randomized Design – CRD
- 2 Permuted Block Design – PBD( $b$ )
- 3 Block Urn Design – BUD( $\lambda$ )
- 4 Mass Weighted Urn Design – MWUD( $\alpha$ )
- 5 Drop-the-Loser Rule – DL( $\alpha$ )
- 6 Doubly Adaptive Biased Coin Design – DBCD( $\gamma$ )
- 7 Constraint Balance Randomization – MaxEnt( $\eta$ ) and MinQD( $\eta$ )

*All the designs depend on a tweak parameter the choice of which is an open question!*

# Randomization Procedures for Unequal Allocations

- 1 Zhao W, Weng Y (2011). “Block urn design. A new randomization algorithm for sequential trials with two or more treatments and balanced or unbalanced allocation”. *Contemporary Clinical Trials* 32, 953-961.
- 2 Zhao W (2015). “Mass weighted urn design. A new randomization algorithm for unequal allocations”. *Contemporary Clinical Trials* 43, 209-216.
- 3 Ivanova A (2003). “A play-the-winner-type urn design with reduced variability”. *Metrika* 58, 1-13.
- 4 Hu F, Zhang LX (2004). “Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials”. *The Annals of Statistics* 32(1), 268-301.
- 5 Titterington DM (1983). “On constrained balance randomization for clinical trials”. *Biometrics* 39(4), 1083-1086
- 6 Klotz JH (1978). “Maximum entropy constrained balance randomization in clinical trials”. *Biometrics* 34(2), 283-287.




# Randomization Procedures for Unequal Allocations

*As to our knowledge, the impact of randomization for the inference has not been considered so far!*



# Randomization Procedures for Unequal Allocations

Target proportions,  $\rho=(0.39, 0.35, 0.26)$






# Randomization Procedures for Unequal Allocations

$$\text{Imbalance: } \text{Imb}(j) = j^{-1} \sqrt{\sum_{k=1}^K (N_k(j) - j\rho_k)^2}, j = 1, 2, \dots, n$$

Maximum Imbalance (MI) vs. Number of Subjects








# Randomization Procedures for Unequal Allocations

Forcing Index:  $FI(j) = j^{-1} \sum_{i=1}^j \sqrt{\sum_{k=1}^K (P_{kj} - \rho_k)^2}, j = 1, 2, \dots, n$


Average Forcing Index (AFI) vs. Number of Subjects





# Randomization Procedures for Unequal Allocations

Allocation Ratio Preserving (ARP) Property:  $\mathbf{E}(P_{kj}) = \rho_k, k = 1, 2, \dots, K.$






# Outline

- 1 Motivation
- 2 Randomization targeting (un)equal allocation
- 3 Simulation study**
- 4 Summary



# Fixed D-optimal Design


Median TTE estimated for D-optimal design.  $b = 0.65$ , sample size = 25 subjects.





# Fixed D-optimal Design


Median TTE estimated for D-optimal design.  $b = 0.65$ , sample size = 50 subjects.





# Two-stage Adaptive D-optimal Design

Average relative  $D$ -efficiency:  $RelEff = \left( \frac{|FIM(\xi^{(2)}, \theta)|}{|FIM(\xi^*, \theta)|} \right)^{1/4}$





UPPSALA  
UNIVERSITET

# Outline

- 1 Motivation
- 2 Randomization targeting (un)equal allocation
- 3 Simulation study
- 4 Summary**



## Summary

- Different randomization procedures have been considered for implementation of D-optimal design for dose-finding studies with TTE outcomes.
- The choice of randomization procedure can be important for implementation of experimental design.
- When the model parameters are known, then the estimation of dose-response curve can be too uncertain when a sample size is small.
- When the model parameters are unknown two-stage adaptive design has been considered. The efficiency of a 2nd stage design may depend on the randomization procedure in the first stage.





UPPSALA  
UNIVERSITET

Thank You!